Reported 2 days ago
Morgan Stanley has initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with an Overweight rating and a price target of $190, praising its potential for regulatory success and estimating $900 million in sales by 2030 for the AXS-05 drug aimed at Alzheimer's disease agitation. The analyst also highlighted the growth of Auvelity for major depressive disorder as a positive factor for the company’s ongoing momentum.
Source: YAHOO